HB1 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Improving Margins And EarningsImproving EBITDA, margins, and earnings indicate that Fuller is converting pricing, mix, and operating execution into stronger profitability. The raised full-year targets reinforce confidence that these gains can persist beyond one quarter and support internally funded investment.
Diversified Specialty Adhesive PlatformFuller’s application-specific adhesive portfolio serves many industrial and consumer-linked markets, reducing dependence on any single customer or end market. Technical formulation and application support can also strengthen customer relationships and support recurring B2B demand.
Improved Liquidity And Debt Maturity ProfileThe refinancing replaces short-term bridge financing with longer-dated facilities, lowers borrowing margins, and expands committed liquidity. That improves funding stability for working capital and debt management, giving Fuller more flexibility while it integrates strategic growth initiatives.
Bears Say
Acquisition-driven Leverage IncreaseThe AMS transaction would materially increase leverage before anticipated synergies are realized, raising interest burden and reducing financial flexibility. Fuller’s plan to return to target leverage within two years depends on successful integration, cash generation, and disciplined capital allocation.
Weak Cash Conversion And Declining Free Cash FlowPositive cash generation is not translating proportionately from reported earnings, and declining free cash flow reduces the resources available for debt reduction, acquisitions, and shareholder returns. Persistent weak conversion could make deleveraging more dependent on operating improvement.
Raw-material Inflation And Supply DisruptionOngoing petrochemical disruption and elevated input costs can pressure margins and complicate pricing pass-through, particularly when customer volumes are soft. The absence of a rapid supply recovery means this remains a meaningful operating constraint over the next several months.
H.B. Fuller Company News
HB1 FAQ
What was H.B. Fuller Company’s price range in the past 12 months?
Currently, no data Available
What is H.B. Fuller Company’s market cap?
H.B. Fuller Company’s market cap is CHF2.19B.
When is H.B. Fuller Company’s upcoming earnings report date?
H.B. Fuller Company’s upcoming earnings report date is Sep 23, 2026 which is in 2 days.
How were H.B. Fuller Company’s earnings last quarter?
H.B. Fuller Company released its earnings results on Jun 24, 2026. The company reported CHF1.16 earnings per share for the quarter, beating the consensus estimate of CHF1.149 by CHF0.011.
Is H.B. Fuller Company overvalued?
According to Wall Street analysts H.B. Fuller Company’s price is currently Undervalued.
Does H.B. Fuller Company pay dividends?
H.B. Fuller Company does not currently pay dividends.
What is H.B. Fuller Company’s EPS estimate?
H.B. Fuller Company’s EPS estimate is 1.21.
How many shares outstanding does H.B. Fuller Company have?
Currently, no data Available
What happened to H.B. Fuller Company’s price movement after its last earnings report?
H.B. Fuller Company reported an EPS of CHF1.16 in its last earnings report, beating expectations of CHF1.149. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of H.B. Fuller Company?
Currently, no hedge funds are holding shares in CH:HB1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
H.B. Fuller Company Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF60.45 (― Upside)
CHF60.45 (― Upside)
Blogger Sentiment
Bullish
CH:HB1 Sentiment 75%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth CHF488.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.50%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
3.83%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
H.B. Fuller Company
H.B. Fuller Company, together with its subsidiaries, formulates, manufactures, and markets adhesives, sealants, coatings, polymers, tapes, encapsulants, additives, and other specialty chemical products. It operates through three segments: Hygiene, Health and Consumable Adhesives; Engineering Adhesives; and Building Adhesive Solutions. The Hygiene, Health and Consumable Adhesives segment produces and supplies specialty industrial adhesives, such as thermoplastic, thermoset, reactive, water-based, and solvent-based products for applications in various markets, including packaging, converting, nonwoven and hygiene, and medical and beauty. The Engineering Adhesives segment produces and supplies high performance industrial adhesives comprising reactive, light cure, two-part liquids, polyurethane, silicone, film, and fast cure products to the durable assembly, performance wood and textile, transportation, electronics, clean energy, aerospace and defense, appliance, heavy machinery, and insulating glass markets. The Construction Adhesives segment provides products used for commercial roofing, heating, ventilation, and air conditioning and insulation applications, as well as caulks and sealants for the consumer market and professional trade. The company sells its products directly to customers, as well as through distributors and retailers in North America, Latin America, Europe, India, the Middle East, Africa, and the Asia Pacific. H.B. Fuller Company was founded in 1887 and is headquartered in Saint Paul, Minnesota.
HB1 Company Deck
HB1 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call was constructive: the company delivered solid Q2 results with revenue, EBITDA, margin and EPS expansion, record second‑quarter cash flow, and clear operational execution amid supply disruptions. Management provided improved full‑year guidance and outlined a strategic, scale‑enhancing acquisition (AMS) with sizable identified synergies that should accelerate medical exposure and margin expansion. Offsetting these positives are continued raw material inflation and supply‑chain disruption, near‑term volume weakness (mid‑single digit expected in H2), and a meaningful near‑term increase in leverage (pro forma ~4x) that prompted investor pushback and share price weakness. Management expects to deleverage within two years and to realize synergies over 2028–2030, but these bring execution and timing risk.View all CH:HB1 earnings summariesHB1 Stock 12 Month Forecast
All Analysts
Top Analysts











